Weekly HIV Pill Held Viral Suppression as Well as Daily Therapy in Phase 3 Trial
Phase 3 ISLEND-1 results in the New England Journal of Medicine found a once-weekly tablet of islatravir 2 mg plus lenacapavir 300 mg was noninferior to once-daily bictegravir, emtricitabine, and tenofovir alafenamide for maintaining HIV viral suppression at 48 weeks in 607 adults already suppressed for at least 6 months. None on weekly therapy had HIV-1 RNA ≥50 copies/mL vs 0.3% on daily. Serious adverse events were 5.3% vs 4.6%.
How this was made
The 30-second read
Why it matters
The newest concrete information is that the weekly regimen met the primary noninferiority endpoint at 48 weeks with no new safety concerns reported, and that serious adverse events were slightly higher in the weekly group. However, the regimen is explicitly not approved and cannot be prescribed, so tradable impact is mostly pipeline optionality until regulatory submissions and longer-term data arrive.
Market read
Traders may reprice pipeline probability for a long-interval HIV regimen based on 48-week noninferiority efficacy and safety signals, but should discount near-term revenue impact due to lack of approval and limited follow-up.
What to watch
The article flags adherence risk differences for missed weekly doses and notes longer follow-up is needed for durability, resistance emergence, and longer-term safety.
Background
Phase 3 ISLEND-1 tested switching already-suppressed adults from daily therapy to a once-weekly combination pill of islatravir and lenacapavir; ISLEND-2 tested switching from multiple daily regimens.
Ticker impact
Article says Gilead Sciences funded Phase 3 ISLEND-1/2 testing a once-weekly islatravir plus lenacapavir regimen for HIV suppression.
Near-term sentiment tailwind for HIV franchise optionality, but likely limited until regulatory submission details and longer-term safety/resistance data are available.
The text provides specific efficacy and safety outcomes at 48 weeks and states the data will support regulatory submissions, but it also notes the regimen is not approved and follow-up is incomplete.
Article states Merck funded the Phase 3 ISLEND trials for a once-weekly islatravir 2 mg plus lenacapavir 300 mg HIV regimen.
Potential positive read-through for pipeline value, with volatility tied to subsequent regulatory milestones and longer follow-up.
The article includes concrete noninferiority efficacy results and safety event rates, but it stops short of approval timing or definitive long-term outcomes.
Market effects
Weekly dosing for HIV could intensify competitive pressure in antiretroviral adherence and regimen convenience, raising expectations for next-gen long-interval therapies.
Limited direct regional impact described; trial conducted across 12 countries, suggesting broad applicability but no specific geography-specific commercial plan.
If approved, a weekly regimen could affect global HIV treatment standards and payer formularies, but the article provides no pricing or access details.
Counterpoint
Noninferiority at 48 weeks is encouraging, but the trial population was already suppressed for at least six months, so the commercial and clinical impact may be narrower than investors assume.
Key entities
- drug_componentislatravir
2 mg component of the once-weekly combination pill tested in Phase 3.
- drug_componentlenacapavir
300 mg component of the once-weekly combination pill tested in Phase 3.
- clinical_trialISLEND-1
Phase 3 double-blind, randomized, active-controlled noninferiority trial with 607 adults across 12 countries.
- clinical_trialISLEND-2
Companion Phase 3 switching trial, open-label, also reaching noninferiority at 48 weeks.
- companyGilead Sciences
Co-funder of the ISLEND trials developing the islatravir component.
